RT Journal Article
SR Electronic
T1 Metabolite inhibition of parent drug biotransformation. Studies of diltiazem.
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 180
OP 182
VO 18
IS 2
A1 Tsao, S C
A1 Dickinson, T H
A1 Abernethy, D R
YR 1990
UL http://dmd.aspetjournals.org/content/18/2/180.abstract
AB Previously, we have demonstrated in vivo, in humans, nonlinear diltiazem disposition with an elimination half-life 50-100% greater after chronic diltiazem as compared to single-dose diltiazem administration. At least two metabolites, desmethyldiltiazem (MA) and desacetyldiltiazem (M1), accumulate significantly in human plasma during chronic diltiazem administration. To test the hypothesis that nonlinear diltiazem accumulation is associated with inhibition of biotransformation, we studied diltiazem disappearance during incubation with a number of its identified metabolites in an isolated rat hepatocyte system. Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM. These apparent ki values are similar to those derived for diltiazem-mediated inhibition of other drug substrates such as antipyrine, the clearance of which is inhibited by diltiazem in vivo in humans. Nonlinear diltiazem accumulation in vivo may be explained in part by progressive metabolite accumulation, particularly MA, which results in the inhibition of parent drug diltiazem biotransformation.